Loading...
•
Dec 31, 2023
Design Therapeutics Q4 2023 Earnings Report
Design Therapeutics reported Q4 2023 financial results and outlined progress across its GeneTAC™ platform.
Key Takeaways
Design Therapeutics reported a net loss of $11.8 million for the fourth quarter of 2023. The company's cash and securities totaled $281.8 million at year-end, supporting a five-year operating runway. Progress was highlighted across the GeneTAC™ platform, including a new drug product for Friedreich Ataxia and IND clearance for Fuchs Endothelial Corneal Dystrophy.
New drug product DT-216P2 for Friedreich Ataxia (FA) shows favorable nonclinical pharmacokinetic and injection site safety profile.
IND cleared for DT-168 for treatment of Fuchs Endothelial Corneal Dystrophy (FECD), with Phase 1 development to start in 2024.
New program unveiled for Huntington’s Disease (HD) targeting reduction of mutant huntingtin with a GeneTAC™ small molecule.
Cash and securities of $281.8 million at year-end 2023 support a five-year operating runway and advancement of up to four programs to clinical proof-of-concept.
Forward Guidance
Design Therapeutics expects cash to fund operating expenses through the next five years.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...